Lactandrate: A D-homo-aza-androsterone alkylator in the treatment of breast cancer

Breast Cancer Research and Treatment

Volumn 97, Issue 1, 2006, Pages 17-31

  Trafalis, Dimitrios T P ^a,b,f   Geromichalos, George D ^c   Koukoulitsa, Catherine ^d   Papageorgiou, Athanasios ^e   Karamanakos, Panayiotis ^e   Camoutsis, Charalambos ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f NONE   (Greece)

Author keywords

Breast cancer; Docking; Estrogen receptor; Homo aza steroids; Human breast xenograft; Human cell lines; Lactam; Murine breast tumors; Steroid alkylators

Indexed keywords

ALKYLATING AGENT; AZASTEROID; CYCLOPHOSPHAMIDE; DEXTRO HOMOAZAANDROSTERONE ALKYLATOR; DOCETAXEL; DOXORUBICIN; ESTER; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; LACTAM; LACTANDRATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CD8F1 TUMOR; CELL STRAIN; CELL STRAIN HS578T; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN MDA MB 435; CELL STRAIN T 549; CELL STRAIN T47D; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG SYNTHESIS; EXPERIMENTAL NEOPLASM; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING DOMAIN; MALE; MOLECULAR MODEL; MOUSE; MX 1 TUMOR; MXT TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE BASED DESIGN; TUMOR MODEL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ALKYLATING AGENTS; ANDROSTERONE; ANIMALS; ANTINEOPLASTIC AGENTS; AZASTEROIDS; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HOMOSTEROIDS; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR STRUCTURE; SECOSTEROIDS; TUMOR CELLS, CULTURED;

EID: 33646719447     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9083-x     Document Type: Article

References (63)

1. Wong ZW, Ellis MJ: First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?. Br J Cancer 90: 20-25, 2004
2. Mouridsen HT, Rose C, Brodie AH, Smith IE: Challenges in the endocrine management of breast cancer. Breast 2(Suppl): S2-19, 2003
3. Catsoulacos P, Politis D, Wampler GL: A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother Pharmacol 3: 67-70, 1979
4. Catsoulacos P, Camoutsis C, Wampler GL: Effect of a Δ5-homo-aza- steroidal ester in P388 and L1210 murine leukemias. Oncology 39: 59-60, 1982
5. Catsoulacos P: Activity of 3β-hydroxy-13α-amino-13,17-seco- 5α-androstan-17-oic-13, 17-lactam p-bis (2-chloroethyl)aminophenoxy acetate (NSC-294859) on experimental tumor and leukemia systems. Oncology 40: 290-292, 1983
6. Catsoulacos P, Wampler GL: Activity of 3β-hydroxy-13α-amino- 13,17-seco-5α-androstan-17-oic-13,17-lactam(p-bis(2-chloroethyl)amino) -phenyl)acetate (NSC-290205) in murine solid tumors. Oncology 39: 109-112, 1982
7. Catsoulacos P: Further studies on the anti-neoplastic activity of 3β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13, 17-lactam(p-bis(2-chloroethyl)amino)phenyl)acetate (NSC-290205). Cancer Lett 22: 199-202, 1984
8. Wall ME, Abernethy SG, Carroll JFI, Taylor DJ: The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J Med Chem 12: 810-818, 1969
9. Wampler GL, Catsoulacos P: Antileukemic effect of homo-aza-steroidal- ester of [p-[bis(2-chloroethyl)amino]acetic acid. Cancer Treat Rep 61: 37-41, 1977
10. Tsai M-J, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486, 1994
11. Beato M, Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17: 587-609, 1996
12. Shiau AK, Barstad D, Loria M, Cheng L, Kushner PJ, Agard DA, Greene GL: . Cell 95: 927-937, 1998
13. Catsoulacos P, Boutis L: Aza-steroids. Beckmann rearrangement of 3β-acetoxy-5α-androstan-17-one oxime acetate with boron fluoride. Alkylting agents. Chim Ther 8: 215-217, 1973
14. Finlay GJ, Wilson WR, Baguley BC: Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 22: 655-662, 1986
15. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res, 48: 589-601, 1988
16. Boyd MR, Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res 34: 91-109, 1995
17. Francisco J, Pauwels O, Simon S, Gasperin P, Van Houtte P, Pasteels JL, Kiss R: Computer-assisted morphonuclear characterization of radiotherapy-induced effects in MXT mouse mammary adenocarcinomas surviving earlier radiotherapy. Int J Radiat Oncol Biol Phys 32: 409-419, 1995
18. Danguy A, Kiss R, Leclercq G, Heuson JC, Pasteels JL: Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur J Cancer Clin Oncol 22: 69-76, 1986
19. Martin DS, Fugmann RA, Stolfi RL, Hayworth PE: Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 5: 89-109, 1975
20. Goldin A, Vendi JM, MacDonald JS, Muggia FM, Henney JE, DeVita VT Jr: Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17: 129-142, 1981
21. Stolfi RL, Martin DS, Fugmann RA: Spontaneous mutine mammary adenocarcinoma: model system for evaluation of combined methods of therapy. Cancer Chemother Rep 55: 239-251, 1971
22. NIH Principles of laboratory animal care. NIH publication 85: 23, 1985
23. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10, 1998
24. Carosati E, Sciabola S, Gabriele C: Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. J Med Chem 47: 5114-5125, 2004
25. Goodford PJ: A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J Med Chem 28: 849-857, 1985
26. Brozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson JÅ, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997
27. Boyer S, Zamora I: New methods in predicting metabolism. J Comput-Aided Mol Des 16: 403-413, 2002
28. Zamora I, Afzelius L, Cruciani G: Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J Med Chem 46: 2313-2324, 2003
29. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O: In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci 17: 183-193, 2002
30. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB: The human CYP3A subfamily: practical considerations. Drug Metab Rev 32: 339-361, 2000
31. Guengerich FP: Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14: 611-650, 2001
32. Crivori P, Zamora I, Speed B, Orrenius C, Poggesi I: Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates. J Comput-Aid Mol Des 18: 155-166, 2004
33. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi J-M, Stark W: Estrogen receptor modulators: identification and structure-relationships of potent ER-selective tetrahydroisoquinoline ligands. J Med Chem 46: 2945-2957, 2003
34. Kekenes-Huskey PM, Muegge I, Rauch M, Gust R, Knapp E-W: A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg Med Chem 12: 6527-6537, 2004
35. Jones KL, Buzdar AU, Jones KL, Buzdar AU: A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 11: 391-406, 2004
36. Leclercq G, Devleeschouwer N, Pairas G, Camoutsis C, Catsoulacos P: Effect of an homo-aza-steroid on estrogen receptor. Meth Find Exp Clin Pharmacol 5: 365-367, 1983
37. Cho W-J, Min SY, Le TN, Kim TS: Synthesis of new 3-arylsoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity. Bioorg Med Chem Lett 13: 4451-4454, 2003
38. De la Fuente JA, Manzanaro S, Martin MJ, de Quesada TG, Reymundo I, Luengo SM, Gago F: Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product. J Med Chem 46: 5208-5221, 2003
39. Sarno S, de Moliner E, Ruzzene M, Pagano MA, Battistuta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA: Biochemical and three-dimensional-structural study of the specific of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J 374: 639-646, 2003
40. Tzukerman MT, Esty A, Santiso-Mere D, Danelian D, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8: 21-30, 1994
41. Kabara JJ, Holzschu DL, Catsoulacos P: Structure function activity of azasterols and nitrogen containing steroids. Lipids 11: 7555-7562, 1976
42. Tsuchiya Y, Nakajima M, Yokoi T: Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 20: 1-10, 2004
43. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N, Ohmori S, Igarashi T, Kitada M: Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42: 15068-15077, 2003
44. Szklarz GD, Halpert JR: Molecular modeling of cytochrome P450 3A4. J Comput Aided Mol Des 1: 265-272, 1997
45. Papageorgiou A, Ivanov IG, Markov GG, Koliais SI, Boutis L, Catsoulacos P: Interaction of homo-aza-steroidal ester of [p-[bis-(2-chloroethyl) amino] acetic acid (ASE) with DNA of Ehrlich ascites tumor cells. FEBS Lett 153: 194-198, 1983
46. Shepherd RE, Huff K, McGuire WL: Brief communication: estrogen receptor interaction with antitumor agent estradiol mustard. J Nat Cancer Inst 53: 895-897, 1974
47. Kubota T, Kawamura E, Suzuki T, Yamada T, Toyoda H, Miyagawa T, Kurokawa T: Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice. Jpn J Clin Oncol 16: 357-564, 1986
48. Catsoulacos P, Catsoulacos D: Antitumor activity of homo-aza-steroidal esters of p-N,N-bis(2-chloroethyl) amino phenoxy acetic acid. Anticancer Res 13: 1203-1208, 1993
49. Camoutsis C, Trafalis DTP: An overview on the antileukemic potential of D-homo-aza- and respective 17β-acetamido-steroidal alkylating esters. Invest New Drugs 21: 47-54, 2003
50. Trafalis DTP, Camoutsis C, Dalezis P, Papageorgiou A, Kontos M, Karamanakos P, Giannakos G, Athanassiou AE: Antitumour effect of A- and D-lactam androgen nitrogen mustards on non-small cell lung carcinoma. J BUON 9: 75-82, 2004
51. Ma D, Wang G, Wang S, Kozikowski AP, Lewin NE, Blumberg PM: Synthesis and protein kinase C binding activity of benzolactam-V-7. Bioorg Med Chem Lett 9: 1371-1374, 1999
52. Endo Y, Shimazu M, Fukasawa H, Driedger PE, Kimura K, Tomioka N, Itai A, Shudo K: Synthesis computer modelling and biological evaluation of novel protein kinase C agonists based on a 7-membered lactam moiety. Bioorg Med Chem Lett 9: 173-178, 1999
53. Endo Y, Yokohama A: Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg Med Chem Lett 10: 63-66, 2000
54. Trafalis DTP, Camoutsis C, Karamanakos P, Arvanitis A, Tegou E, Ziras N, Athanassiou AE: Preclinical evaluation of the homo-aza-steroidal ester: 13β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13, 17-lactam-p-bis(2-chloro ethyl) aminophenoxy acetate for the treatment of malignant melanoma. J BUON 8: 333-339, 2003
55. Catsoulacos P, Politis D, Wampler GL: Antitumor activity of homo-aza-steroidal esters of [p-bis(2-chloroethyl)amino]phenyl]acetic acid [p-bis(2-chloroethyl)amino] phenyl]butyric acid. Cancer Chemother Pharmacol 10: 129-132, 1983
56. Catsoulacos P, Camoutsis C, Papageorgiou A, Adamiak-Margariti E: Cytostatic effect of homo-aza-steroidal esters in vivo and in vitro structure-activity relationships. Anticancer Res 12: 1617-1620, 1992
57. Dalmases P, Gomez-Belinchon JI, Bonet J-J, Giner-Sorolla A, Schmid FA: Antineoplastic agents II. A nitrogen mustard derivative of N-methylated steroidal lactam. Eur J Med Chem 18: 541-543, 1983
58. Dalmases P, Cervantes G, Quintana J, Bonet J-J: Antineoplastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams. Eur J Med Chem 19: 465-467, 1984
59. Catsoulacos P, Papageorgiou A, Margariti E, Mourelatos D, Mioglou E: Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity. Oncology 51: 74-78, 1994
60. Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP: A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 97: 537-544, 2003
61. Zelek L , Barthier S, Riofrio M, Sevin D, Fizazi K, Spielmann M: Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. Ann Oncol 12: 1265-1268, 2001
62. Kubota T, Abe O, Izuo M, Watanabe H, Enomoto K, Ohsawa N, Kuno K: A phase II multi-institutional study of estra-1,3,5(10)-triene-3,17 beta-diol, 3-benzoate, 17[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1- oxobutoxy]acetate] (KM2210), a novel antitumor agent, for advanced and recurrent breast carcinoma. Anticancer Res 13: 2361-2365, 1993
63. Kubota T, Ishibiki K, Abe O, Kosano H, Ohsawa N, Hoffman RM: Mode of action of estra-1,3,5(10)-triene-3, 17 beta-diol, 3-benzoate, 17[4-[4-[bis(2-chloroethyl) amino]phenyl]-1-oxobutoxy] acetate] (KM2210) on MCF-7 human breast tumours transplanted into nude mice. Anticancer Res 13: 935-940, 1993